Document is current
Any future updates will be listed below
-
Authors
Wu, Yun
Han, Yiqun
Li, Qing
Zhang, Pin
Yuan, Peng
Luo, Yang
Fan, Ying
Chen, Shanshan
Cai, Ruigang
Li, Qiao
Xu, Hangcheng
Wang, Yan
Ma, Fei
Wang, Jiayu https://orcid.org/0000-0003-1967-389X
Xu, Binghe
-
Funding
Funding for this research was provided by:
China Anti-Cancer Association- Scientific Research Foundation of Anti-HER2 Targets Therapy
- License Information
-
More Information
Article History
Received: 5 January 2022
Accepted: 27 February 2022
First Online: 16 March 2022
Declarations
:
: The authors have no relevant financial or non-financial interests to disclose.
: The trial was conducted in accordance with the principles of Good Clinical Practice as specified in the Declaration of Helsinki. The study protocol was approved by the Institutional Ethics Committee of Cancer Hospital, Chinese Academy of Medical Sciences (ID: 14–062/852), and all the participants provided written informed consent.
